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Abstract Epigenetics studies inheritable changes of genes
and gene expression that do not concern DNA nucleotide
variation. Such modifications include DNA methylation,
several forms of histone modification, and microRNAs.
From recent studies, we know not only that genetic changes
account for heritable phenotypic variation, but that epigenet-
ic changes also play an important role in the variation of
predisposition to disease and to drug response. In this review,
we discuss recent evidence of epigenetic changes that play
an important role in the development of cardiac hypertrophy
and heart failure and may dictate response to therapy.
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Introduction
There is wide variability in an individual’s disease predispo-
sition and response to treatment, which is partially ascribed to
heritable factors [1]. However, based on recent whole-
genome association studies, we have to conclude that
variation in nucleotides does not account for all the heritable
phenotypic variation [2–4]. In addition to variation in
nucleotides, epigenetic variations may play a critical role in
controlling gene expression and therefore offer another
mechanism to explain interindividual variation [5].
Epigenetics studies inheritable changes of genes and
gene expression that do not concern the original DNA
nucleotide variations, such as mutations or polymorphisms.
Three different types of epigenetic variations are known to
alter gene expression control: methylation of genomic
DNA, modification of histone proteins, and regulatory
noncoding RNAs, such as microRNAs (Fig. 1). All three
mechanisms concern extrinsic factors that can modulate the
transcription of genes, even though the protein-encoding
regions of the genes themselves are unchanged [6]. These
epigenetic control mechanisms may differ among tissues
and individuals, but they also may change in time during
aging or as a result of environmental interactions or
diseases. Because the epigenome plays a critical role in
programming the expression of the genome, differences in
gene expression among individuals that affect the response
to drugs may be modified by epigenomic variations on top
of nucleotide mutations or polymorphisms. Therefore,
epigenetic changes currently are being considered in
clinical medicine complementary to nucleotide variations
at the drug response level [7]. This rapidly emerging novel
discipline, called pharmacoepigenetics, involves the study
of epigenetic factors in the interpersonal variation to drugs
but also the discovery of novel pharmacologic targets [8]. It
is expected that pharmacoepigenetics (jointly with pharma-
cogenetics) will play a crucial role in future pharmacology
and clinical medicine [7].
So far, most advances in pharmacoepigenetics have been
derived from the oncology field—for example, studies
characterizing the interindividual differences of cytochrome
P-450 (reviewed by Ingelman-Sundberg et al. [9]). Fortunate-
ly, the knowledge of the role of epigenetic modifications is
being translated to other complex and heterogeneous con-
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Epigenetic Modifications and Heart Failure
Histone Modifications
The large eukaryotic genome is compacted tightly as a
result of its association with highly conserved histone
proteins. In the nucleosomes, genomic DNA is folded and
compacted around core histone proteins (two copies of each
of the core histones H2A, H2B, H3, and H4), forming the
basic repeat units of chromatin. The interaction of genomic
DNA with these chromosomal proteins has a major
influence on the accessibility of transcriptional factors to
their target DNA sequences and thereby regulates tran-
scriptional activity (Fig. 1)[ 10•]. Through this mechanism,
nucleosomes carry epigenetically inherited information in
the form of covalent modifications of their core histones.
Such modifications include acetylation, methylation, phos-
phorylation, ubiquitination, and sumoylation of histone
Fig. 1 Epigenetic modifications at different genetic levels and their
effect on drug response. Environmental factors generate a spectrum of
phenotypes in the population through the participation of epigenetic
mechanisms such as covalent modification of DNA (ie, methylation)
and histones and expression of regulatory noncoding RNA molecules
such as microRNAs (miRNAs). Epigenetic factors affect the expres-
sion of drug transporters, drug-metabolizing enzymes, nuclear
receptors that regulate the expression of various genes, and even drug
targets. The dynamic state of epigenetics, as opposed to a rather
established nucleotide sequence, provides the basis for an individual’s
response to a constantly changing environment. Methylation of DNA
provides an impediment to transcription factors and the transcription
machinery by attracting proteins that affect chromatin configuration.
Posttranslational modifications of the N-terminal of the histone
proteins (and their various combinations) affect the compaction of
the chromatin; that is, methylation of lysine at position 9 of histone 3 or
H3K9me is a signature of heterochromatin or compact DNA, whereas
acetylation of lysine at position 14 of histone 3 or H3K14ac—and
sometimes in combination with phosphorylation of proline at position
10 of histone 3 or H3P10p—creates a more open chromatin confi-
guration (euchromatin) that allows transcription of genes. miRNA
molecules arise from miRNA genes, which, when transcribed, can
promoteposttranscriptional regulationbycomplementarity with the 3′-
untranslated region of target mRNAs and their subsequent degrada-
tion. ER—estrogen receptor; HDAC—histone deacetylase inhibitor;
PXR—pregnane X receptor; RAR—retinoic acid receptor. (Adapted
from Gomez and Ingelman-Sundberg [35]; with permission from
Macmillan Publishers Ltd: Clinical Pharmacology and Therapeutics
[85:426–430], © 2009.)
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that sticks out from the chromatin fiber and is thought to
interact with DNA or other histone or proteins. Lysine and
arginine residues within this tail are the main targets for
histone modification. Most research was aimed at under-
standing the role of lysine acetylation and methylation. It
turns out that lysine acetylation is associated mainly with
chromatin accessibility and transcription, whereas the effect
of lysine methylation varies depending on which residue is
modified [11].
Interestingly, as reviewed by Mano [10•], the regulation
of histone acetylation has been linked to cardiac hypertro-
phy. The acetylation of histone tails by histone acetyltrans-
ferases is required for the induction of hypertrophic
changes in cardiac muscle cells by phenylephrine. Consis-
tent with this are the results of studies focused on class II
histone deacetylases (HDACs) 5 and 9, which exert
antihypertrophic effects by inhibiting the activity of myo-
cyte enhancer factor 2 (MEF2) and further blocking the
expression of pro-hypertrophic genes [12]. Contrary to
these findings, class I HDACs have rather pro-hypertrophic
effects by regulating the expression of phosphatidylinositol
(3, 4, 5)-triphosphate phosphatase, which modulates hyper-
trophy [13]. This means that HDACs control muscle cell
size on multiple levels.
DNA Methylation
In eukaryotes, DNA methylation occurs by the addition of a
methyl group to the carbon 5′ position of the nucleotide
cytosine ring. In mammals, DNA methylation occurs mainly
in the sequence 5′-CG-3′, which also is referred to as a CpG
dinucleotide; approximately 70% of all CpGs in humans are
methylated [14]. On the other hand, unmethylated CpGs are
found in the 5′ regulatory regions of many genes as clusters
called “CpG islands.” This frequency of CpG dinucleotides
in CpG islands is higher than that found in other DNA
regions. Notably, differential methylation of CpG islands is
part of the epigenetic variation found in humans [15].
DNA cytosine methylation alters the accessibility for
transcription factor complexes at a local level and, as with
histone modifications, affects chromatin structure at regional
andgenome-widelevels.Thus,awell-characterizedfunctional
effect of DNA methylation is control of gene expression [16].
In this respect, hypermethylation of CpG sites may silence a
gene, whereas hypomethylation allows gene transcription.
One might say that methylation is a stable and heritable
modification, but at the same time, it may be affected by the
environment. For example, the mouse agouti locus, which
affects coat color, is affected by the methylation status of an
upstream transposon. Genetically identical parents in whom
agouti genes are in different epigenetic states tend to produce
offspring with different coat colors [17].
Experimental evidence for a role in transcriptional
regulation for HF-specific genes by DNA methylation
came from a recent study by Kao et al. [18]. They showed
that the proinflammatory gene TNF-α reduces expression
of the sarcoplasmic reticulum Ca
2+-ATPase (SERCA2A) by
enhancing methylation status of the SERCA2A promoter
region. Movassagh et al. [19•] recently showed there are
methylation status differences between cardiomyopathy and
controls in human cardiac tissue. Furthermore, they
identified three loci (PECAM1, PECAM1, AMOTL2) whose
differential methylation is correlated with altered gene
expression in different cardiac samples.
MicroRNAs
MicroRNAs (miRNAs or miR) are short (∼20 bp) double-
strand RNA molecules that originate from nuclear and
cytoplasmic larger precursors and act as important regu-
lators of gene expression at a posttranscriptional level.
miRNAs fine-tune the expression of 30% to 50% of the
protein-coding genes by binding to partly complementary
base pairs in 3′ untranslated regions of mRNAs, thereby
interfering with translation; targeted mRNAs are either
degraded or temporarily silenced [20]. miRNA regulation
of protein expression is very complex because several
miRNAs can target the same gene and several genes may
be targeted by the same miRNA [20]. The expression of
miRNAs is tissue and disease specific. In recent years, a
molecular miRNA signature has been identified in many
pathologic conditions, ranging from various types of cancer
to many aspects of CVD [21•].
Growing evidence indicates that miRNAs are involved in
basic cell functions [22]. The link between miRNAs and
several aspects of HF are now very clear, and the number of
publications in this field has increased rapidly in the past few
years (Table 1). Research on CVDs has focused mainly on
the two miRNA families specifically expressed in heart tissue
(miRNA-1/miRNA-133 and miRNA-208). Several studies
investigated miRNA expression in the healthy heart, during
pressure overload, and in different etiologies of human,
mouse, and rat HF, as reviewed by Divakaran and Mann
[23]. van Rooij et al. [24] determined that the cardiac-specific
miRNA-208 regulates cardiomyocyte hypertrophy, fibrosis,
and expression of β-myosin heavy chain (β-MHC) in
response to stress and hypothyroidism. This miRNA is
encoded by an intron of the α-MHC gene. Thus, the gene
encoding α-MHC, in addition to encoding a major cardiac
contractile protein, regulates cardiac growth and gene
expression in response to stress and hormonal signaling
through miRNA-208, via targets of miRNA-208 such as β-
MHC. Furthermore, targeted deletion of the muscle-specific
miRNA, miRNA-1-2, revealed numerous functions in the
heart, including regulation of cardiac morphogenesis, electri-
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showed that the miRNA signature of failing myocardium
closely resembles the miRNA expression pattern of fetal
heart, and this underlies the reonset of the fetal gene program
in failing hearts. Another interesting study by Thum et al.
[27] showed that miRNA-21 regulates the ERK-MAP kinase
pathway specifically in cardiac fibroblasts, not in cardiomyo-
cytes, and this affects cardiac structure and function.
Increased miRNA-21 levels in fibroblasts activate ERK
kinase activity through inhibition-specific genes, and by this
mechanism, miRNA-21 regulates interstitial fibrosis and
cardiac hypertrophy. These findings revealed an extra level
of gene regulation via miRNA-mediated paracrine secretion,
in this case via cardiac fibroblasts.
The profound effects of miRNAs on the heart and the
hypertrophic response are subject to further study, and
miRNAs are emerging as chief regulators of gene control.
Thus far, miRNAs have been shown to affect the
myocardium but also the electrical properties of the heart,
as well as the modulation of angiogenesis [28].
Methods of Epigenetic Screening
Epigenomic profiles vary from cell type to cell type and
may change over time and in response to physiologic,
pathologic, and pharmacologic triggers. Therefore, map-
ping the epigenome, as a follow-up to the human genome
Table 1 Cardiac microRNAs, their functions, and validated targets
MiR
family
Function Validated cardiac targets
All
(Dicer)
Regulation of cardiogenesis Not applicable
Cardiomyocyte-specific deletion in mice is embryonically
[25] or neonatally [44] lethal (depending on promotor)
1 Embryonic
Modulates cardiogenesis [25, 45–47] Delta, the Notch ligand, involved in cardiac cell differentiation [45];
Hand2, a cardiac transcription factor involved in cardiomyocyte
expansion [25, 46]; and HDAC4, a transcriptional repressor of muscle
gene expression [47]
Essential to maintain muscle gene expression [45]
Deletion in mice is partially embryonically lethal
(ventricular–septal defect) [25]
Regulation of cardiomyocyte cell cycle [25]
Adult
Conduction [25]; proarrhythmic [48–51] Irx5, a cardiac TF that represses the potassium channel Kcnd2 [18];
potassium channels KCNJ2 [48] and KCNE1 [51]; pacemaker channels
HCN2 and HCN4 [50]; connexin 43 [48]; and B56α subunit of protein
phosphatase 2A [49]
Regulation of cardiomyocyte growth [52, 53] Pro-hypertrophic genes calmodulin and Mef2a [52]; cell cycle regulators
RasGAP and Cdk9 and Rheb [53]; and fibronectin [31]
Proapoptotic [54] HSP60 and HSP70 [54]
133 Embryonic
Modulates cardiogenesis [47, 55] SRF [47, 55]
Deletion in mice is partially embryonically lethal
(ventricular–septal defect) [55]
Regulation of cardiomyocyte cell cycle [55] Cyclin D2 [55]
Adult
Regulation of collagen synthesis [55, 56] CTGF [56]
Conduction [55]; proarrhythmic [50, 57] Potassium channels KCNQ [51] and HERG [57] and pacemaker channel
HCN2 [50]
Regulation of cardiomyocyte growth [22, 58] RhoA, a GDP–GTP exchange protein regulating cardiac hypertrophy [22];
Cdc42, a signal transduction kinase implicated in hypertrophy [22]; and
Nelf-A/WHSC2, a nuclear factor involved in cardiogenesis [22]
Antiapoptotic [54, 55] Caspase-9 [54]
208 Adult
Regulates cardiomyocyte hypertrophy and fibrosis in
response to pressure overload
THRAP1, a thyroid hormone transcription factor [24]
GDP—guanosine diphosphate; GTP—guanosine triphosphate; TF—transcription factor.
(From Schroen and Heymans [20]; with permission.)
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possible to determine the epigenetic status of a sequence in
the genome, mapping the entire epigenome will require the
sequencing of dozens of genomes covering all the different
cell types of an organism at different points in life [7].
Bisulfite mapping is the most accurate method for
mapping DNA methylation patterns. Genomic DNA is
treated with sodium bisulfite, which results in modification
and eventual deamination of the unmethylated cytosines to
uracil, whereas the methylated cytosines are protected from
this conversion. To determine the methylation state of
specific genes, gene-specific primers are used to amplify
the sequence of interest, which is then subjected to
sequencing. Methylated cytosines register as Cs, whereas
unmethylated cytosines appear as Ts in the sequence [7].
Several whole-genome approaches to methylation map-
ping were developed recently that are based on the
differential sensitivity of methylated and unmethylated
CpGs to restriction enzymes. Restriction length genome
scanning uses a double-digestion of DNA with a frequent-
cutter methylation-insensitive restriction enzyme and a rare
methylation-sensitive enzyme such as Not1, which cleaves
its recognition site exclusively when it is unmethylated [7].
A different whole-genome approach that takes advantage of
DNA chip technology allows rapid profiling of the status of
methylation of thousands of CpG islands at once, using the
differential methylation hybridization method [29]. This
method is used to identify CpG islands, which are
methylated in tumor samples relative to their normal
controls.
An alternative to bisulfite conversion is the ChIP-seq
(chromatin immunoprecipitation combined with sequencing)
technology. Protein-DNA interactions are crosslinked in situ
followed by immunoprecipitation and sequencing of genome-
wide sites associated with a modification of interest. This
approach allows the identification of DNA binding sites of
any DNA-associated protein. This technique also provides
information on histone modifications (acetylation, methyla-
tion, phosphorylation, ubiquitination, and sumoylation). Var-
iations on the ChIP technology have been developed, such as
the “DCS” method, which couples ChIP with subtraction
polymerase chain reaction (PCR) [30, 31]. This technique
aims to avoid the nonspecific signals generated by hybrid-
ization of genome-derived fragments to microarrays.
In the same manner, to examine the role of miRNAs in
human pathology, most studies have used high-throughput
methods to analyze global miRNA expression in clinical
samples [32]. High-throughput methods are represented by
microRNA microarray and quantitative real-time PCR.
Although the discrimination between molecules represents
a great challenge, the main advantage of miRNA microarray
is represented by the high specificity of the reaction, whereas
the main disadvantage is represented by low sensitivity [21•].
Drugs Modifying the Epigenetic Status
Epigenetics modulates phenotypic variation in health and
disease, and it seems likely that understanding and
manipulating the epigenome hold enormous promise for
preventing and treating common human illnesses. Epige-
netics also offers an important window to understanding the
role of the environment’s interactions with the genome in
causing disease, and in modulating those interactions to
improve human health [33].
Antagomirs are single-strand RNAs complementary to the
miRNA. Chemical modification of antagomirs might repre-
sent a very attractive approach to targeting pathologic
miRNAs. However, this strategy is challenging because
miRNAs all belong to closely related families and the
specificity of antagomirs for one miRNA might be difficult
to achieve. Furthermore, a single miRNA targets several
genes; among them, some might be beneficial for the
myocardium. In that regard, chemically modified oligonu-
cleotides that would specifically disrupt the binding between
the miRNA and a single mRNA might be good therapeutic
candidates.However,theinvivofinaleffectofthemodulation
of miRNAs remains unclear, because each of them can target
hundreds of genes with different intensity [28]. Finally, the
challenges in bringing miRNA antagonists to the clinical
arena are similar to the ones we encountered with gene
therapy, namely the mode of delivery, vectors, specificity,
and toxicity in vivo [34]. At least theoretically, targeting
specific miRNAs implicated in ischemic heart disease,
cardiac hypertrophy, HF, angiogenesis, and channelopathies
might turn out to be an attractive therapeutic tool in the
future, aiming to prevent the development of HF [28].
An alternative approach would be to target DNA
methylation. Several chemical compounds that affect the
genomic DNA methylation landscape already are being
used in the clinic. Drugs such as 5-azacytidine and
azacytidine inhibit methyltransferases, causing demethyla-
tion of DNA sequences. Other drugs inhibit DNA methyl-
ation by blocking the maintenance methyltransferase. For
more detailed information, see the article by Gomez and
Ingelman-Sundberg [35]. The lack of specificity of the
current drugs, however, leads to a global effect, which
might affect genomic stability. Drugs that can target a
specific methylation site have yet to be designed. In
addition to work involving drugs that modify DNA
methylation, increasing work is being carried out in
developing drugs that affect histone modifications.
HDAC inhibitors have been the focus of attention in
anticancer drug development because they are seen as
presenting a potential strategy to reverse aberrant epigenetic
changes associated with cancer [36]. There also is evidence
that HDAC inhibitors may restore gene expression pro-
grams in cardiomyocyte hypertrophy. Gallo et al. [37]
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using trichostatin A and sodium butyrate.
Epigenetics and Environment
It is known that environmental factors such as toxins and
diet may have an effect on DNA methylation and chromatin
modification and that these changes are passed on to the
next generation [38, 39]. Estrogenic and antiandrogenic
toxins that decrease male fertility alter DNA methylation,
and these changes are inherited by subsequent generations
[39]. The hypothesis that environmental factors alter
heritable epigenetic marks and change patterns of gene
expression is an exciting possibility in human disease
research. Most common diseases are influenced by both
genetic and environmental factors; thus, environmentally
induced changes in epigenetic structures may provide a
mechanistic link between genes and the environment [40].
Age plays an important role in gene-environment
interactions. Common diseases increase with aging, which
is related to the accumulation of epigenetic changes through
the lifetime of an individual. This idea is supported by a study
showing higher levels of variation of total DNA methylation
and histone H3K9 acetylation in older monozygotic twins
than in younger twins, although that study did not measure
epigenetic changes over time in the same individual [41].
Conclusions
The field of epigenetics offers a new playground for
researchers to study and modify interindividual variation
in clinical effects, variation in drug response and toxicity,
and new targets for drug therapy. The increasing knowledge
regarding epigenetic mechanisms derived from the Human
Epigenome Project is leading to a better understanding of
human disease and a new range of molecular targets for
epigenetic drugs [42]. Although most advances in pharma-
cogenomics have been applied to its use in the oncology
field, this review presents evidence that in the past years,
there has been a significant increase in the number of
cardiovascular epigenetic studies, and in miRNAs more
specifically [8]. The review by Mishra et al. [43] offers a
clear picture of the recent progress made in the microR-
Nomics of CVD and the future of miRNAs as potential
therapeutic targets or drug agents.
As epigenetics has an important rolein shaping phenotypic
variation in health and disease, it seems likely that under-
standing and manipulating the epigenome hold enormous
promise for preventing and treating common human diseases,
including CVD and HF.
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